FrancophonIA/ELRC3.0 huggingface dataset:
English: The median OS for the overall population (n = 663) was 13.4 months for the pemetrexed arm and 10.6 months for the placebo arm, hazard ratio = 0.79 (95 % CI = 0.65 - 0.95, p = 0.01192).
Estonian: Uldise elulemuse mediaan kõikidel uuringus osalenutel (n = 663) oli 13,4 kuud pemetrekseedi rühmas ja 10,6 kuud platseeborühmas, riskisuhe = 0,79 (95% CI = 0,65…0,95; p = 0,01192).
English: The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in > 5 % of 839 patients with NSCLC who were randomized to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomized to receive cisplatin and gemcitabine.
Estonian: Alljärgnevas tabelis on esitatud kõrvaltoimete esinemissagedus ja raskusaste, millel arvati võimalikku seost uuringuravimiga ja mida täheldati rohkem kui 5%-l 839-st mitteväikerakk-kopsuvähki (MVRKV) põdevast patsiendist, kes olid randomiseeritud tsisplatiini ja pemetrekseedi rühma, ja 830st MVRKV-d põdevast patsiendist, kes olid randomiseeritud tsisplatiini ja gemtsitabiini rühma.
English: In patients with mild to moderate renal insufficiency eligible for pemetrexed therapy NSAIDs with long elimination half-lives should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.5).
Estonian: Pemetrekseedravile määratud kerge või mõõduka neerupuudulikkusega patsiendid peavad katkestama pika eliminatsiooni poolväärtusajaga MSPVR-ide kasutamise vähemalt 5 päeva enne, manustamispäeval ja vähemalt 2 päeva pärast pemetrekseedi manustamist (vt lõik 4.5).
English: Clinically relevant CTC toxicities that were reported in < 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Estonian: Kliiniliselt olulisteks CTC toksilisusteks, mida registreeriti < 1%-l patsientidest, kes olid randomiseeritult määratud tsisplatiini ja pemetrekseedi gruppi, olid arütmia ja motoorne neuropaatia.
English: Log Rank p-value* Overall response rate** (95 % CI)
Estonian: Logaritmilise astaktesti p-väärtus* Üldine ravivastus** (95% CI)
English: Clinically relevant CTC toxicities that were reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Estonian: Kliinilise tähtsusega CTC toksilisusteks, mida registreeriti ≥ 1% ja 5%-l patsientidest, kes olid randomiseeritult määratud pemetrekseedi gruppi, olid neutropeeniata infektsioon, neutropeenia palavikuga, allergiline reaktsioon/ülitundlikkus, kreatiniini taseme tõus, motoorne neuropaatia, sensoorne neuropaatia, erythema multiforme ja kõhuvalu.
English: − if you start feeling chest pain (common) or having a fast heart rate (uncommon)
Estonian: − kui teil tekib valu rinnus (sage) või suureneb südame löögisagedus (aeg-ajalt);
English: Contraception in males and females Women of childbearing potential must use effective contraception during treatment with pemetrexed.
Estonian: Fertiilses eas naised peavad pemetrekseedravi ajal kasutama efektiivseid rasestumisvastaseid vahendeid.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/15/1038/003
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/15/1038/003
English: JMEN: Kaplan Meier plots of progression-free survival (PFS) and overall survival pemetrexed versus placebo in patients with NSCLC other than predominantly squamous cell histology
Estonian: JMEN: Kaplani-Meieri graafikud progressioonivaba elulemuse (PFS) ja üldise elulemuse kohta pemetrekseedi rühmas võrreldes platseeboga muu kui prevaleeruvalt lamerakulise histoloogiaga mitteväikerakk-kopsuvähiga patsientidel
English: − if you are breast-feeding; you must discontinue breast-feeding during treatment with
Estonian: − kui te toidate last rinnapiimaga, siis peate ravi ajaks Pemetrexed medac'iga imetamise katkestama
English: What Pemetrexed medac is and what is it used for Pemetrexed medac is a medicine used in the treatment of cancer.
Estonian: Pemetrexed medac on ravim, mida kasutatakse vähktõve raviks.
English: Common Vomiting Mucositis/ stomatitis
Estonian: Oksendamine Anoreksia Kõhukinnisus Stomatiit/farüngiit
English: Pemetrexed/ Cisplatin (N = 168)
Estonian: Pemetrekseed/ tsisplatiin (N = 168)
English: Clinically relevant CTC toxicity that was reported in < 1 % of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.
Estonian: Kliiniliselt oluline CTC toksilisus, mida kirjeldati < 1% patsientidest, kes randomiseeriti saama pemetrekseedi, hõlmab järgimisi kõrvaltoimeid: allergiline reaktsioon/ülitundlikkus, multiformne erüteem, neerupuudulikkus, supraventrikulaarne arütmia ja kopsu trombemboolia.
English: Median overall survival (months) (95 % CI)
Estonian: Üldise elulemuse (kuud) (95% CI)
English: For the purpose of this table a cut off of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
Estonian: Selles tabelis kasutati 5%-list äralõiget, et kaasata kõiki juhtumeid, mille puhul peeti võimalikuks seost pemetrekseediga.
English: Neuropathy-sensory 10.1 Common Taste disturbance
Estonian: Sensoorne neuropaatia Maitseaistingu häired
English: MARKETING AUTHORISATION NUMBER(S) EU/1/15/1038/002
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/15/1038/002
English: MARKETING AUTHORISATION NUMBER(S) EU/1/15/1038/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/15/1038/001
English: Pemetrexed medac in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Estonian: Pemetrexed medac kombinatsioonis tsisplatiiniga on näidustatud eelnevalt keemiaravi mittesaanud patsientide raviks, kel esineb mitteresetseeritav pleura maliigne mesotelioom.
English: Common Neuropathy-sensory 7.4
Estonian: Sensoorne neuropaatia
English: How to use Pemetrexed medac
Estonian: Kuidas Pemetrexed medac'i kasutada
English: Pemetrexed medac contains sodium
Estonian: Pemetrexed medac sisaldab naatriumi
English: For patients with NSCLC other than predominantly squamous cell histology (n = 430, independently reviewed population) median PFS was 4.4 months for the pemetrexed arm and 1.8 months for the placebo arm, hazard ratio = 0.47 (95 % CI = 0.37 - 0.60, p = 0.00001).
Estonian: Muu kui prevaleeruvalt lamerakulise histoloogiaga mitteväikerakk-kopsuvähiga patsientidel (n = 430, sõltumatult hinnatud populatsioon) oli PFS mediaan4,4 kuud pemetrekseedi rühmas ja 1,8 kuud platseeborühmas, riskisuhe = 0,47, 95% CI = 0,37…0,60, p = 0,00001.
English: Table 2 - Dose modification table for pemetrexed (as single agent or in combination) and cisplatin - Non-haematologic toxicitiesa,b
Estonian: Tabel 2 - Annuse muutmise tabel pemetrekseedi (üksi või kombinatsioonis) ja tsisplatiini kohta - mittehematoloogiline toksilisusa, b Pemetrekseedi annus Tsisplatiini annus (mg/m²)
English: Pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
Estonian: Pemetrexed medac kombinatsioonis tsisplatiiniga on näidustatud esimese rea raviks patsientidel, kel esineb lokaalselt kaugelearenenud või metastaseerunud mitteväikerakk kopsuvähk, mis ei ole prevaleeruvalt lamerakulise histoloogiaga (vt lõik 5.1).
English: Pemetrexed medac is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer.
Estonian: Pemetrexed medac'i kasutatakse ka kombinatsioonis tsisplatiiniga kopsuvähi kaugelearenenud staadiumis patsientidel esialgseks raviks.
English: Pemetrexed medac 100 mg: Each vial contains 100 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Pemetrexed medac 100 mg: iga viaal sisaldab 100 mg pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: You must take at least 5 doses during the seven days before the first dose of Pemetrexed medac.
Estonian: Enne Pemetrexed medac'i esimest annust peate seitsme päeva jooksul võtma vähemalt 5 annust.
English: CTC
Estonian: PC GC
English: You will always receive Pemetrexed medac by infusion into one of your veins.
Estonian: Pemetrexed medac'i manustatakse teile alati infusioonina veeni.
English: Pemetrexed medac is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
Estonian: Pemetrexed medac'i monoteraapia on näidustatud teise rea ravina patsientidele, kel esineb lokaalselt kaugelearenenud või metastaseerunud mitteväikerakk kopsuvähk, mis ei ole prevaleeruvalt lamerakulise histoloogiaga (vt lõik 5.1).
English: Pemetrexed has a steady-state volume of distribution of 9 l/m².
Estonian: Pemetrekseedi jaotusruumala tasakaalukontsentratsiooni korral on 9 l/m².
English: NAME OF THE MEDICINAL PRODUCT Pemetrexed medac 100 mg powder for concentrate for solution for infusion Pemetrexed medac 500 mg powder for concentrate for solution for infusion Pemetrexed medac 1,000 mg powder for concentrate for solution for infusion
Estonian: RAVIMPREPARAADI NIMETUS Pemetrexed medac 100 mg infusioonilahuse kontsentraadi pulber Pemetrexed medac 500 mg infusioonilahuse kontsentraadi pulber Pemetrexed medac 1000 mg infusioonilahuse kontsentraadi pulber
English: * P-values < 0.05 comparing pemetrexed/cisplatin to gemcitabine/cisplatin, using Fisher Exact test ** Refer to National Cancer Institute CTC (v2.0; NCI 1998) for each Grade of Toxicity *** According to National Cancer Institute CTC (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2
Estonian: ** Toksilisuse iga astme kohta vt NCI CTC (v2,0; NCI 1998) *** Vastavalt NCI CTC-le (v2,0; NCI 1998) tuleb maitseaistingu häireid ja alopeetsiat registreerida ainult 1. või 2. astmena.
English: If patients develop non-haematologic toxicities ≥ Grade 3 (excluding neurotoxicity), pemetrexed should be withheld until resolution to less than or equal to the patient's pre-therapy value.
Estonian: Kui patsiendil tekivad mittehematoloogilise toksilisuse nähud ≥ 3. aste (välja arvatud neurotoksilisus),
English: Common (may affect up to 1 in 10 people)
Estonian: Sage (võib esineda kuni 1 patsiendil 10'st)
English: During the study, low-dose folic acid and vitamin B12 supplementation was introduced to patients' therapy to reduce toxicity.
Estonian: Ravi toksilisuse vähendamiseks lisati uuringu kestel täiendavalt väikeses annuses foolhapet ja B12-vitamiini .
English: Clinically relevant CTC toxicities that were reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Estonian: Kliiniliselt olulisteks CTC toksilisusteks, mida registreeriti ≥ 1%-l ja ≤ 5%-l patsientidest, kes olid randomiseeritult määratud tsisplatiini ja pemetrekseedi gruppi, olid: neerupuudulikkus, infektsioon, palavik, neutropeenia palavikuga, ASAT, ALAT ja GGT tõus, urtikaaria ja valu rinnus.
English: Stomatitis/
Estonian: Kõhukinnisus
English: The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (n = 472, independently reviewed population; median of 3.9 months and 2.6 months, respectively) (hazard ratio = 0.64, 95 % CI = 0.51 - 0.81, p = 0.0002).
Estonian: Pemetrekseedi grupis olid PFS'i osas statistiliselt olulised paremad näitajad võrreldes platseebogrupiga (n = 472, sõltumatult hinnatud populatsioon; vastavalt keskmiselt 3,9 kuud ja 2,6 kuud) (riskide suhe = 0,64, 95% CI = 0,51…0,81, p = 0,0002).
English: Clinically relevant toxicity that was reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Estonian: Kliiniliselt oluliste toksilisuse juhtudena, mida täheldati sagedusega ≥ 1% ja ≤ 5% patsientidest, kes olid randomiseeritud tsisplatiini ja pemetrekseedi rühma, olid ASAT tõus, ALAT tõus, infektsioon, febriilne neutropeenia, neerupuudulikkus, palavik, dehüdratsioon, konjunktiviit ja kreatiniini kliirensi vähenemine.
English: How to store Pemetrexed medac
Estonian: Kuidas Pemetrexed medac'i säilitada
English: − fast heart rate
Estonian: Väga sage Väsimus Sage
English: Pemetrexed medac 500 mg powder for concentrate for solution for infusion Each vial contains 500 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Pemetrexed medac 500 mg infusioonilahuse kontsentraadi pulber Üks viaal sisaldab 500 mg pemetrekseedi (dinaatriumpemetrekseed hemipentahüdraadina).
English: Women must use effective contraception during treatment with Pemetrexed medac.
Estonian: Ravi ajal Pemetrexed medac'iga peavad naised kasutama efektiivseid rasestumisvastaseid vahendeid.
English: Uncommon (may affect up to 1 in 100 people)
Estonian: Aeg-ajalt (võib esineda kuni 1 patsiendil 100'st)
English: Pemetrexed medac 1,000 mg powder for concentrate for solution for infusion Each vial contains 1,000 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Pemetrexed medac 1000 mg infusioonilahuse kontsentraadi pulber Üks viaal sisaldab 1000 mg pemetrekseedi (dinaatriumpemetrekseed hemipentahüdraadina).
English: Including the induction phase the median OS for patients with NSCLC other than predominantly squamous cell histology was 18.6 months for the pemetrexed arm and 13.6 months for the placebo arm, hazard ratio = 0.71 (95 % CI = 0.56 - 0.88, p = 0.002).
Estonian: Kui induktsioonfaas kaasa arvata, oli muu kui prevaleeruvalt lamerakulise histoloogiaga mitteväikerakkkopsuvähiga patsientidel üldise elulemuse mediaan 18,6 kuud pemetrekseedi rühmas ja 13,6 kuud platseeborühmas (riskisuhe = 0,71, 95% CI = 0,56…0,88, p = 0,002).
English: From the start of pemetrexed plus cisplatin first line induction treatment, the median OS of patients was 16.9 months for the pemetrexed arm and 14.0 months for the placebo arm (hazard ratio = 0.78, 95 % CI = 0.64 - 0.96).
Estonian: Alates pemetrekseedi/tsisplatiini esimese rea induktsioonravist oli üldise elulemuse mediaan pemetrekseedi grupis 16,9 kuud ja platseebogrupis 14,0 kuud (riskisuhe = 0,78, 95% CI = 0,64...0,96).
English: Efficacy of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma Randomized and treated patients
Estonian: Pemetrekseedi ja tsisplatiini efektiivsus võrreldes tsisplatiiniga pleura maliigse mesotelioomi korral
English: Pharmacotherapeutic group: antineoplastic agents, folic acid analogues, ATC code: L01BA04 Pemetrexed medac is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.
Estonian: Farmakoterapeutiline rühm: kasvajavastased ained, foolhappe analoogid, ATC-kood: L01BA04
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Vial
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Viaal
English: Pemetrexed medac 1,000 mg: Each vial contains 1,000 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Pemetrexed medac 1000 mg: iga viaal sisaldab 1000 milligrammi pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: Cases of radiation recall have been reported in patients who received radiotherapy weeks or years previously.
Estonian: Nädalaid või aastaid varem kiiritusravi saanud patsientidel on täheldatud kiiritusravist tingitud löövet.
English: − loss of appetite
Estonian: Düspepsia/ kõrvetised
English: Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in association with other chemotherapeutic agents.
Estonian: Ainult pemetrekseedi manustamisel või koos teiste kemoterapeutiliste ravimitega manustamisel on teatatud tõsistest neerukahjustustest, sealhulgas ägedast neerupuudulikkusest.
English: The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes.
Estonian: Vastav kogus pemetrekseedi lahust tuleb lahjendada veel ilma säilitusaineta naatriumkloriidi 9 mg/ml (0,9%) süstelahusega, et saaks 100 ml valmislahust, mida manustatakse veenisisese infusioonina 10 minuti jooksul.
English: − increased urine output
Estonian: Kreatiniini tõus
English: Pemetrexed medac 500 mg: Each vial contains 500 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Pemetrexed medac 500 mg: iga viaal sisaldab 500 milligrammi pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: Clinically relevant toxicity that was reported in < 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Estonian: Kliiniliselt oluliste toksilisuse juhtumitena, mida täheldati sagedusega < 1% patsientidest, kes olid randomiseeritud tsisplatiini ja pemetrekseedi rühma, olid GGT tõus, rindkerevalu, arütmia ja motoorne neuropaatia.
English: Clinically relevant CTC toxicity of any grade that was reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to pemetrexed include: febrile neutropenia, infection, decreased platelets, diarrhoea, constipation, alopecia, pruritus/itching, fever (in the absence of neutropenia), ocular surface disease (including conjunctivitis), increased lacrimation, dizziness and motor neuropathy.
Estonian: kes randomiseeriti saama pemetrekseedi, hõlmab järgimisi kõrvaltoimeid: febriilne neutropeenia, infektsioon, trombotsüütide arvu langus, kõhulahtisus, kõhukinnisus, alopeetsia, sügelus, palavik (neutropeenia puudumisel), silma pindmine haigus (sh konjunktiviit), suurenenud pisaravool, pearinglus ja motoorne neuropaatia.
English: Constipation Stomatitis/
Estonian: Stomatiit/ farüngiit
English: Common Conjunctivitis
Estonian: Konjunktiviit
English: Common Leukocytes decreased
Estonian: Leukotsüütide arvu vähenemine Neutrofiilide arvu vähenemine
English: NAME OF THE MEDICINAL PRODUCT Pemetrexed medac 100 mg powder for concentrate for solution for infusion pemetrexed
Estonian: RAVIMPREPARAADI NIMETUS Pemetrexed medac 100 mg infusioonilahuse kontsentraadi pulber pemetrekseed
English: NAME OF THE MEDICINAL PRODUCT Pemetrexed medac 500 mg powder for concentrate for solution for infusion pemetrexed
Estonian: RAVIMPREPARAADI NIMETUS Pemetrexed medac 500 mg infusioonilahuse kontsentraadi pulber pemetrekseed
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Pemetrexed medac 100 mg powder for concentrate for solution for infusion pemetrexed
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Pemetrexed medac 100 mg infusioonilahuse kontsentraadi pulber pemetrekseed
English: Reconstitute 500 mg vials with 20 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Estonian: Lahustage 500 mg viaali sisu 20 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega, mis ei sisalda säilitusainet, mille tulemusena saate lahuse, mis sisaldab pemetrekseedi 25 mg/ml.
English: NAME OF THE MEDICINAL PRODUCT Pemetrexed medac 1,000 mg powder for concentrate for solution for infusion pemetrexed
Estonian: RAVIMPREPARAADI NIMETUS Pemetrexed medac 1000 mg infusioonilahuse kontsentraadi pulber pemetrekseed
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 1,000 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Iga viaal sisaldab 1000 mg pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: Pharyngitis
Estonian: Tsisplatiin
English: Reconstitute 100 mg vials with 4.2 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Estonian: Lahustage 100 mg viaali sisu 4,2 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega, mis ei sisalda säilitusainet, mille tulemusena saate lahuse, mis sisaldab pemetrekseedi 25 mg/ml.
English: − chest pain
Estonian: Valu Turse
English: − upset stomach
Estonian: Oksendamine Mukosiit/stomatiit
English: Reconstitute 1,000 mg vials with 40 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Estonian: Lahustage 1000 mg viaali sisu 40 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega, mis ei sisalda säilitusainet, mille tulemusena saate lahuse, mis sisaldab pemetrekseedi 25 mg/ml.
English: − kidney failure
Estonian: Lööve/ketendus
English: − anaphylactic shock (severe allergic reaction)
Estonian: Seedetrakti häired Väga sage Kõhulahtisus Oksendamine
English: Granulocytes decreased
Estonian: Võimalikud kõrvaltoimed
English: Pemetrexed/ cisplatin (N = 839)
Estonian: Esinemissagedus Kõrvaltoime** Pemetrekseed/ tsisplatiin (N = 839)
English: Therefore, caution should be made when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).
Estonian: Normaalse neerufunktsiooniga patsientidel (kreatiniini kliirens ≥ 80 ml/min), kellele manustatakse pemetrekseedi, tuleb kasutada MSPVA-sid või aatsetüülsalitsüülhapet suuremates annustes ettevaatlikult.
English: − low haemoglobin level (anaemia)
Estonian: Väga sage Hemoglobiini sisalduse langus
English: The median OS for patients with NSCLC other than predominantly squamous cell histology (n = 481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95 % CI = 0.56 - 0.88, p = 0.002).
Estonian: Muu kui prevaleeruvalt lamerakulise histoloogiaga mitteväikerakkkopsuvähiga patsientidel (n = 481) oli üldine elulemuse mediaan 0,56…0,88, p = 0,002).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 100 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Iga viaal sisaldab 100 mg pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 500 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Iga viaal sisaldab 500 mg pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: The volume of distribution (Vss) is approximately 21 litres.
Estonian: Jaotusruumala (Vss) on ligikaudu 21 liitrit.
English: • age ≥ 75 years
Estonian: • vanus ≥ 75 aastat
English: OTHER sun as symbol moon as symbol
Estonian: päikese sümbol kuu sümbol
English: These medicinal products should not be administered simultaneously.
Estonian: Mainitud ravimeid ei tohi samaaegselt manustada.
English: Take the medicine pack with you, even if there are no tablets left.
Estonian: Võtke ravimipakend endaga kaasa, isegi kui tablette ei ole enam järel.
English: Take the card
Estonian: Võtke see kaart.
English: Ethnic origin and race
Estonian: Etniline kuuluvus ja rass
English: Separate your language as needed (this is facilitated by the perforated edges)
Estonian: Vajadusel eraldage soovitud keeleversioon (seda lihtsustavad perforeeritud servad).
English: Other medicines and Eliquis
Estonian: Muud ravimid ja Eliquis
English: Try to take the tablets at the same times every day to have the best treatment effect.
Estonian: Püüdke parima ravitulemuse saavutamiseks võtta tablette iga päev samal ajal.
English: Table 2 System Organ Class
Estonian: Tabel 2 Organsüsteemi klass
English: Your doctor will decide how long you must continue treatment for.
Estonian: Teie arst otsustab, kui kaua te peate ravimit võtma.
English: Take Eliquis regularly as instructed.
Estonian: • Võtke Eliquisi regulaarselt vastavalt juhistele.
English: Your doctor might change your anticoagulant treatment as follows:
Estonian: Teie arst võib teie antikoagulantravi muuta järgnevalt: